Selected by a team of medicinal chemists and pharmacists for high chemical and pharmacological diversity, as well as for known bioavailability and safety in humans.
|A unique collection of 1280 small molecules, 95% approved drugs (FDA, EMA and other agencies)|
|Designed to increase potential "high-quality" hits|
|A constant quality control ensures high purity compounds and stability of compounds|
|Over the past 17 years, “hit-likeness” and “hit-workability” were reported by users in
|PCL® Premium||PCL® Full Premium|
|Formulation||1280 molecules||1280 molecules|
|Format||10 mM in DMSO||10 mM in DMSO|
|Stability||5 years at -20°C||5 years at -20°C|
|Quantity||100 µL / compound||100 µL / compound|
|Database||Virtual file and USB key
(Excel®, sdf, rdf, db, pdf)
|Virtual file and USB key
(Excel®, sdf, rdf, db, pdf
|Plate and plate map customization||96 well plates (Greiner)|
|Hit follow-up (Expert Med Chem Services)||Not included||FREE Med Chem assistance:
Hit classification into chemical families
/ series and analog search
|Hit Re-supply||Not included||FREE: up to 20 compounds|
at International Meetings
The Prestwick Chemical Library® (PCL) is Prestwick’s flagship product dedicated to screening. It is a collection of 1280 molecules comprising 100% approved drugs (FDA, EMEA and other agencies) selected for their high chemical and pharmacological diversity. These off-patent drugs have known bioavailability and safety data in humans are available. The PCL was designed to reduce the risk of "low quality" hits and therefor the cost of the initial screening, and appears to be an efficient smart library for hit discovery.
The ensuing project was designed to optimize the benefits of the PCL®1 through pharmacophore modelling. The pharmacophore characterization of the library was obtained by applying a multi-step approach, first starting with a clustering analysis based RDF pharmacophore similarity. The 1280 compounds of the PCL were found to be clustered in 385 groups: 217 clusters and 168 singletons were obtained. The aim of this work was to generate a model for each cluster and subsequently use these models for extending the PCL and have a pharmacophoric representation of the library. After evaluation on the Zinc 2 database, a random selection of pharmacophore models underwent an external validation process by using DrugBank3 and ChEMBL4 databases.
PD’s high prevalence (~1 million patients in the US), severe consequencesto the patients’ quality of life and high cost (est. $25 billion pa cost in the US). Both thesereasons make the search for a cure imperative. Traditional target based approaches havenot yet been fruitful. In an alternative approach, we chose to follow a repurposing approachand screen a library of previously safety approved drug compounds for neuroprotectiveactivity against PD using a Drosophila model of the disease.